|Articles|October 1, 2018

Does being an orphan speed up FDA approval?

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Pharmaceutical Executive Daily: FDA Grants Traditional Approval to Novartis's Fabhalta

ByNicholas Jacobus

July 17th 2026

FDA Approves Fabhalta to Slow Kidney Function Decline in Primary IgAN in Adults

ByNicholas Jacobus

July 17th 2026

Jasper Therapeutics to Acquire Kira Pharmaceuticals in $132 Million Merger Agreement

ByNicholas Jacobus

July 17th 2026

From Dr. Google to Dr. Claude: Why the Most Important Patient Support Innovation Is Still Human Connection

ByMichael Oleksiw

July 17th 2026

How Nuvation Bio Manages its Ongoing Clinical Trials

ByMike Hollan,David Hung

July 17th 2026

Does being an orphan speed up FDA approval?

Related Content

Pharmaceutical Executive Daily: FDA Grants Traditional Approval to Novartis's Fabhalta

FDA Approves Fabhalta to Slow Kidney Function Decline in Primary IgAN in Adults

Jasper Therapeutics to Acquire Kira Pharmaceuticals in $132 Million Merger Agreement

From Dr. Google to Dr. Claude: Why the Most Important Patient Support Innovation Is Still Human Connection

How Nuvation Bio Manages its Ongoing Clinical Trials

Trending on PharmExec

Jasper Therapeutics to Acquire Kira Pharmaceuticals in $132 Million Merger Agreement

FDA Approves Lipfendra to reduce LDL-C in Adults with Hypercholesterolemia

Pharmaceutical Executive Daily: FDA Grants Traditional Approval to Novartis's Fabhalta

How Nuvation Bio Manages its Ongoing Clinical Trials

FDA Approves Fabhalta to Slow Kidney Function Decline in Primary IgAN in Adults